Use of Rituximab in the Treatment of Nephrotic Glomerulonephritis (TURING): Effect of Achieved Remission Status on the Risk of Relapse (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0820; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "As in the main trial, patients in CR maintained remission for longer than those only achieving PR. Conclusion Rituximab is effective in maintaining remission from NS in adults with MCD and FSGS with a greater efficacy for patients who achieve CR than PR."
Clinical • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease
|
|
Megan Griffith; Wendi Qian; Colin C. Geddes; David R.W. Jayne; Andreas Kronbichler; Lisa Willcocks
|